Ascletis Tweaks Its Oral GLP-1 Strategy After Mixed Dose Results

Ascletis Pharma Inc. has been testing an oral GLP-1 drug called ASC30 in early-stage clinical trials for weight loss.

Now it has looked at new data and realized something important.

A high starting dose with fast dose increases is not better. In fact, it gives similar weight loss but worse tolerability compared to slower, more gradual dosing.

So the company is changing its approach.

Why ASC30 matters in the first place

ASC30 is part of a very competitive drug class called GLP-1 receptor agonists.

These drugs are known for:

• Reducing appetite 

• Supporting weight loss 

• Improving metabolic health 

Right now, most successful GLP-1 drugs are injections.

So the big race in pharma is to create an oral version that works just as well but is easier to take.

That is where ASC30 fits in.

What the new trial data looked at

The latest update comes from the third cohort of a Phase 1b study.

This group of patients was tested with a different dosing strategy compared to earlier groups.

There were 7 patients in this cohort.

The key difference was how the drug was given:

• Earlier cohorts started at lower doses and increased slowly 

• This third cohort started higher and increased faster 

So this was basically a “fast and aggressive” dosing experiment.

What the results showed

After 28 days, the average weight loss in the third cohort was 4.8%.

But there is an important detail here.

Two patients had much lower weight loss (only 1.8%), which pulled down the average.

When those outliers are removed, the result looks better and is more in line with earlier cohorts.

Key comparisons:

• Cohort 2 showed about 6.5% placebo-adjusted weight loss 

• Cohort 3 showed about 6.1% placebo-adjusted weight loss after adjustment 

• Maximum weight loss was similar across cohorts, around 9% 

So effectiveness was basically similar.

The real difference was tolerability.

The real problem: side effects

Even though the drug worked similarly across dosing strategies, side effects were not equal.

The company reported:

• No severe (grade 3 or higher) adverse events 

• Most side effects were mild and short-lived 

But the high-start, fast-titration approach still performed worse in terms of how patients tolerated it.

The main issue was gastrointestinal discomfort, which is very common in GLP-1 drugs.

So even if the weight loss is similar, the patient experience is not.

What Ascletis is changing now

Based on these results, Ascletis Pharma Inc. is moving away from the high starting dose strategy.

Instead, it is shifting toward:

• Lower starting doses 

• Slower dose increases 

• More gradual titration over time 

The goal is simple: keep effectiveness but improve comfort.

Why dosing strategy matters so much here

With GLP-1 drugs, dosing is not just a technical detail.

It directly affects:

• How sick patients feel at the start 

• Whether they stay on treatment 

• Overall real-world effectiveness 

If side effects are too strong early on, patients may stop treatment even if the drug works well.

So companies spend a lot of time fine-tuning dose escalation schedules.

Where ASC30 fits in the bigger GLP-1 race

The oral GLP-1 space is extremely competitive right now.

Big pharma companies are all trying to build the first successful pill version of this drug class.

Some key players include:

• Novo Nordisk, which is currently ahead in oral GLP-1 development 

• Eli Lilly and Company, which recently reported strong oral GLP-1 data 

• Several smaller biotech firms also trying to catch up 

The goal is to move beyond injections like Wegovy and Zepbound and create a daily pill version that is easier for patients.

How big the market is

Weight loss drugs are already becoming one of the biggest drug markets in the world.

The current injectable therapies are already blockbuster products.

But an oral version would:

• Be easier for patients to take 

• Potentially increase adoption 

• Expand the total market size 

So this is not a small scientific experiment. It is a multi-billion-dollar competition.

What Ascletis is doing strategically

Ascletis Pharma Inc. is now focusing heavily on obesity and metabolic diseases.

To do that, it is:

• Reducing spending on viral disease programs 

• Cutting back on liver disease and oncology projects 

• Redirecting resources toward metabolic drug development 

So the company is basically going all-in on this area.

What happens next

The company has already submitted a Phase 2a trial plan to the U.S. FDA.

The next study is expected to:

• Last around 13 weeks 

• Start in the U.S. early in the third quarter 

• Further test dosing and effectiveness of ASC30 

This will be a more important test of whether the drug can compete in the real obesity drug market.

Final takeaway

Here is the simple version.

ASC30 is showing that oral GLP-1 drugs can produce meaningful weight loss, around 6% in early studies.

But how you give the drug matters just as much as the drug itself.

Fast, high starting doses do not improve results and make side effects worse.

So Ascletis is switching to a slower and gentler dosing strategy as it moves into the next phase of development.

The bigger goal is still the same: build a competitive oral weight loss drug in a market that is already heating up fast.